{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:00:25Z","timestamp":1792839625288,"version":"4.5.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":672,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1002\/hep.26466","type":"journal-article","created":{"date-parts":[[2013,5,17]],"date-time":"2013-05-17T09:38:52Z","timestamp":1368783532000},"page":"2070-2078","source":"Crossref","is-referenced-by-count":89,"title":["Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis"],"prefix":"10.1097","volume":"58","author":[{"given":"N\u00faria","family":"Gua\u00f1abens","sequence":"first","affiliation":[{"name":"Metabolic Bone Diseases Unit; Service of Rheumatology, Hospital Cl\u00ednic, IDIBAPS, University of Barcelona; Barcelona Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas, CIBERehd; Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Monegal","sequence":"additional","affiliation":[{"name":"Metabolic Bone Diseases Unit; Service of Rheumatology, Hospital Cl\u00ednic, IDIBAPS, University of Barcelona; Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dacia","family":"Cerd\u00e1","sequence":"additional","affiliation":[{"name":"Metabolic Bone Diseases Unit; Service of Rheumatology, Hospital Cl\u00ednic, IDIBAPS, University of Barcelona; Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1frica","family":"Mux\u00ed","sequence":"additional","affiliation":[{"name":"Service of Nuclear Medicine; Hospital Cl\u00ednic, IDIBAPS; Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Gifre","sequence":"additional","affiliation":[{"name":"Metabolic Bone Diseases Unit; Service of Rheumatology, Hospital Cl\u00ednic, IDIBAPS, University of Barcelona; Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Peris","sequence":"additional","affiliation":[{"name":"Metabolic Bone Diseases Unit; Service of Rheumatology, Hospital Cl\u00ednic, IDIBAPS, University of Barcelona; Barcelona Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas, CIBERehd; Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Par\u00e9s","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas, CIBERehd; Barcelona Spain"},{"name":"Liver Unit; Hospital Cl\u00ednic, IDIBAPS, University of Barcelona; Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2013,10,29]]},"reference":[{"key":"10.1002\/hep.26466-BIB0001|hep26466-cit-0001","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1053\/j.gastro.2010.02.016","article-title":"Low bone mass and severity of choslestasis affect fracture risk in patients with primary biliary cirrhosis","volume":"138","author":"Gua\u00f1abens","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1002\/hep.26466-BIB0002|hep26466-cit-0002","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0168-8278(01)00144-1","article-title":"Bone disease in primary biliary cirrhosis: independent indicators and rate of progression","volume":"35","author":"Menon","year":"2001","journal-title":"J Hepatol"},{"key":"10.1002\/hep.26466-BIB0003|hep26466-cit-0003","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0168-8278(91)90941-4","article-title":"Longitudinal study on osteodystrophy in primary biliary cirrhosis (PBC) and a pilot study on calcitonin treatment","volume":"12","author":"Floreani","year":"1991","journal-title":"J Hepatol"},{"key":"10.1002\/hep.26466-BIB0004|hep26466-cit-0004","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0168-8278(92)90066-X","article-title":"Sodium fluoride prevents bone loss in primary biliary cirrhosis","volume":"15","author":"Gua\u00f1abens","year":"1992","journal-title":"J Hepatol"},{"key":"10.1002\/hep.26466-BIB0005|hep26466-cit-0005","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s10620-006-8015-x","article-title":"Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen\/progestin","volume":"51","author":"Boone","year":"2006","journal-title":"Dig Dis Sci"},{"key":"10.1002\/hep.26466-BIB0006|hep26466-cit-0006","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-2796.2004.01342.x","article-title":"An open, randomized, controlled study of transdermal hormonal replacement therapy on the rate of bone loss in primary biliary cirrhosis","volume":"256","author":"Ormasd\u00f3ttir","year":"2004","journal-title":"J Int Med"},{"key":"10.1002\/hep.26466-BIB0007|hep26466-cit-0007","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1478-3231.2005.01026.x","article-title":"Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study","volume":"25","author":"Levy","year":"2005","journal-title":"Liver Int"},{"key":"10.1002\/hep.26466-BIB0008|hep26466-cit-0008","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0016-5085(97)70098-2","article-title":"Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years","volume":"113","author":"Gua\u00f1abens","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1002\/hep.26466-BIB0009|hep26466-cit-0009","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1111\/j.1572-0241.2003.07639.x","article-title":"Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis","volume":"98","author":"Gua\u00f1abens","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1002\/hep.26466-BIB0010|hep26466-cit-0010","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0168-8278(00)80118-X","article-title":"Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial","volume":"33","author":"Lindor","year":"2000","journal-title":"J Hepatol"},{"key":"10.1002\/hep.26466-BIB0011|hep26466-cit-0011","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/hep.20866","article-title":"Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial","volume":"42","author":"Zein","year":"2005","journal-title":"Hepatology"},{"key":"10.1002\/hep.26466-BIB0012|hep26466-cit-0012","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0168-8278(97)80048-7","article-title":"Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis","volume":"26","author":"Wolfhagen","year":"1997","journal-title":"J Hepatol"},{"key":"10.1002\/hep.26466-BIB0013|hep26466-cit-0013","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1056\/NEJMp1202623","article-title":"Continuing bisphosphonate treatment for osteoporosis-for whom and for how long?","volume":"366","author":"Black","year":"2012","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1002\/hep.26466-BIB0014|hep26466-cit-0014","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/S0168-8278(10)60186-9","article-title":"Monthly ibandronate vs weekly alendronate in the treatment of osteoporosis associated with primary biliary cirrhosis. Similar efficacy but different adherence","volume":"52","author":"Pares","year":"2010","journal-title":"J Hepatol"},{"key":"10.1002\/hep.26466-BIB0015|hep26466-cit-0015","first-page":"CD009144","article-title":"Bisphosphonates for osteoporosis in primary biliary cirrhosis","volume":"12","author":"Rudic","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1002\/hep.26466-BIB0016|hep26466-cit-0016","first-page":"168","volume-title":"Osteoporosis. Oxford","author":"Kanis","year":"1994"},{"key":"10.1002\/hep.26466-BIB0017|hep26466-cit-0017","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1002\/hep.26466-BIB0018|hep26466-cit-0018","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","article-title":"Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1002\/hep.26466-BIB0019|hep26466-cit-0019","unstructured":"International Osteoporosis Foundation The adherence gap: why osteoporosis patients don't continue with treatment www.osteofund.org\/publications\/adherence_gap_report.html 2005"},{"key":"10.1002\/hep.26466-BIB0020|hep26466-cit-0020","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1002\/hep.26466-BIB0021|hep26466-cit-0021","volume-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843","author":"World Health Organization","year":"1994"},{"key":"10.1002\/hep.26466-BIB0022|hep26466-cit-0022","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","article-title":"Concurrent and predictive validity of a self-reported measure of medication adherence","volume":"24","author":"Morisky","year":"1986","journal-title":"Med Care"},{"issue":"Suppl 1","key":"10.1002\/hep.26466-BIB0023|hep26466-cit-0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/gut.50.suppl_1.i1","article-title":"Guidelines on the management of osteoporosis associated with chronic liver disease","volume":"50","author":"Collier","year":"2002","journal-title":"Gut"},{"key":"10.1002\/hep.26466-BIB0024|hep26466-cit-0024","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0016-5085(03)01062-X","article-title":"American Gastroenterological Association Clinical Practice Commitee. AGA technical review on osteoporosis in hepatic disorders","volume":"125","author":"Leslie","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1002\/hep.26466-BIB0025|hep26466-cit-0025","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.abb.2010.05.030","article-title":"Liver and bone","volume":"503","author":"Gua\u00f1abens","year":"2010","journal-title":"Arch Biochem Biophys"},{"key":"10.1002\/hep.26466-BIB0026|hep26466-cit-0026","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jhep.2006.06.007","article-title":"Treatment of bone disorders in liver disease","volume":"45","author":"Par\u00e9s","year":"2006","journal-title":"J Hepatol"},{"key":"10.1002\/hep.26466-BIB0027|hep26466-cit-0027","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1007\/s00198-006-0082-5","article-title":"Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation","volume":"17","author":"Atamaz","year":"2006","journal-title":"Osteoporos Int"},{"issue":"Suppl 1","key":"10.1002\/hep.26466-BIB0028|hep26466-cit-0028","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.bone.2006.01.150","article-title":"Adherence, patient preference and dosing frequency: understanding the relationship","volume":"38","author":"Reginster","year":"2006","journal-title":"Bone"},{"key":"10.1002\/hep.26466-BIB0029|hep26466-cit-0029","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00198-006-0322-8","article-title":"A systematic review of persistence and compliance with bisphosphonates for osteoporosis","volume":"18","author":"Cramer","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1002\/hep.26466-BIB0030|hep26466-cit-0030","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1185\/030079905X61875","article-title":"Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis","volume":"21","author":"Cramer","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1002\/hep.26466-BIB0031|hep26466-cit-0031","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2005.044958","article-title":"Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study","volume":"65","author":"Regynster","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1002\/hep.26466-BIB0032|hep26466-cit-0032","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1742-1241.2011.02806.x","article-title":"Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis","volume":"66","author":"Lin","year":"2012","journal-title":"Int J Clin Pract"},{"key":"10.1002\/hep.26466-BIB0033|hep26466-cit-0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03339822","article-title":"Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging Clin Exp Res"},{"key":"10.1002\/hep.26466-BIB0034|hep26466-cit-0034","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1210\/jc.2006-1526","article-title":"Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis","volume":"92","author":"Delmas","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1002\/hep.26466-BIB0035|hep26466-cit-0035","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bone.2012.03.026","article-title":"25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis","volume":"51","author":"Peris","year":"2012","journal-title":"Bone"},{"key":"10.1002\/hep.26466-BIB0036|hep26466-cit-0036","doi-asserted-by":"crossref","unstructured":"Cryer B Bauer DC Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 2002 77 1031 1043","DOI":"10.4065\/77.10.1031"},{"key":"10.1002\/hep.26466-BIB0037|hep26466-cit-0037","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/hep.21852","article-title":"Bone disorders in chronic liver disease","volume":"46","author":"Collier","year":"2007","journal-title":"Hepatology"},{"key":"10.1002\/hep.26466-BIB0038|hep26466-cit-0038","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/MJT.0b013e3181d7e1d3","article-title":"Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis","volume":"18","author":"Treeprasertsuk","year":"2011","journal-title":"Am J Ther"},{"key":"10.1002\/hep.26466-BIB0039|hep26466-cit-0039","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00198-011-1756-1","article-title":"Patients with cirrhosis and ascites have false values of bone density","volume":"23","author":"Gua\u00f1abens","year":"2012","journal-title":"Osteoporos Int"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.26466","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/hep.26466\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T07:41:52Z","timestamp":1673422912000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hep.26466"}},"subtitle":["HEPATOLOGY, Vol. 00, No. X, 2013 GUA\u00d1ABENS ET AL."],"short-title":[],"issued":{"date-parts":[[2013,10,29]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.26466","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718011393.793479910","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.718011393.793478939","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.718011393.793478189","asserted-by":"object"}]},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10,29]]}}}